Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Event-driven oncology trade: recent positive AMTAGVI data (strong response and disease-control rates) and 50% ORR in a sarcoma pilot have driven a ~100% move off midâFebruary lows, with earnings also beating on revenue and margins. With multiple upcoming TIL program updates and manufacturing transition milestones, IOVA remains a high-volatility name where additional clinical or commercialization news could trigger further short-term upside swings.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Recovery ⢠Strong Liquidity ⢠Heavy Cash Burn IOVA shows improving margins and strong liquidity, but persistent cash burn, dilution, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong upward trend ⢠Overbought momentum ⢠Key resistance nearby Support Level: $8.00â$8.10; stronger support $7.00â$7.10 Resistance Level: $8.99â$9.00 IOVA gained 39% over the last month to $8.79, signaling strong momentum above its moving average but an overbought RSI warrants caution near $9.00 resistance.
Sentiment & News
Key News Insights: ⢠Revenue beat ⢠Margin expansion ⢠Clinical catalysts Iovance's Amtagvi outperformance, improving margins, and upcoming clinical catalysts are driving strong bullish momentum, though execution remains key.
AI Summary
Iovance has shifted from a clinical-stage story to a commercial execution bet: Amtagvi's accelerating revenue and 56% gross margin support scalable economics, but after the sharp rerating investors should demand sustained center throughput and declining cash burn to avoid further dilutive financing.
Description
Iovance Biotherapeutics is a clinical-stage biotechnology company that develops cell-based cancer immunotherapies using patients' own immune cells to target tumors. Its lead candidates, including lifileucel and LN-145, are being evaluated in multiple phase 2 trials for indications such as metastatic melanoma, cervical cancer and head and neck cancer. The company maintains collaborations and licensing arrangements with academic cancer centers and pharmaceutical partners, was founded in 2007, changed its name from Lion Biotechnologies in 2017, and is headquartered in San Carlos, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | IOVA | Iovance Biotherapeutics, Inc. | Event-driven oncology trade: recent positive AMTAGVI data (strong response and disease-control rates) and 50% ORR in a sarcoma pilot have driven a ~100% move off midâFebruary lows, with earnings also beating on revenue and margins. With multiple upcoming TIL program updates and manufacturing transition milestones, IOVA remains a high-volatility name where additional clinical or commercialization news could trigger further short-term upside swings. | Closed | -25.2% |
| Feb 25 | Mar 4 | IOVA | Iovance Biotherapeutics, Inc. | Nearâterm biotech momentum play: strong new clinical data (â50â52% ORR, 73% disease control in lifileucel/Amtagvi programs) and a large gapâup (~31% 21âday gain, ~39% above 21âday SMA) ahead of the 2026â02â24 Q4/webcast create a highâvolatility breakout with active newsflow and technical followâthrough potential over the next few days. | Closed | +11.2% |